Resting state EEG rhythms as network disease markers for drug discovery in alzheimer's disease

Claudio Babiloni, Francesco Infarinato, Antonio I. Triggiani, Roberta Lizio, Claudio Del Percio, Nicola Marzano, Jill C. Richardson

Research output: Contribution to journalArticlepeer-review

Abstract

Alzheimer's disease (AD) induces a widespread patho-logical extracellular accumulation of beta-amyloid (Ab) peptides that affects cortical networks underpin- ning cognitive functions. This is related to abnormal functional and effective brain connectivity as revealed by graph markers of resting-state eyes-closed electro-encephalographic (EEG) rhythms. Here we revised EEG studies in mild cognitive impairment and AD subjects showing that these markers are promising network disease endpoints for basic research and AD drug discovery.

Original languageEnglish
Pages (from-to)e85-e90
JournalDrug Discovery Today: Therapeutic Strategies
Volume10
Issue number2
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Resting state EEG rhythms as network disease markers for drug discovery in alzheimer's disease'. Together they form a unique fingerprint.

Cite this